The nutraceutical revolution:

9th Nutraceutical Conference

May 20, 21, 2002, The Waldorf-Astoria, New York

(Re: Foods, Dietary Supplements & Medical Foods)

ITS IMPACT ON THE FOOD & DRUG INDUSTRIES

FIM, as a continuation of the Nutraceutical Initiative, announces a one and a half day conference which will address the impact of the Nutraceutical Revolution on corporate research, development and commercialization of foods, dietary supplements and medical foods. The regulatory and commercial distinctions between the food and drug industries continue to blur. For this reason all three major nutraceutical categories have been included in the program. The conference moderator will be Stephen L. DeFelice, M.D. and the program will be divided into three sections as follows:

SECTION I

THE BOUNDARIES & CORPORATE FLEXIBILITY REGARDING HEALTH-MEDICAL CLAIMS

Opinions of legal experts vs. opinions of non-legal experts such as corporate executives and medical authorities on the range of freedom regarding making health-medical claims will be presented. There is little doubt that corporate confusion regarding what can and what cannot be claimed has had a significant inhibiting effect on the research, development and commercialization of nutraceuticals. Case histories will be discussed, including Pharmanex, and a panel discussion will be included in this segment of the program. Anticipated future Congressional and FDA activities regarding health-medical claims will also be presented.

SECTION II

INFORMATION REGARDING MARKET PATTERNS AND RESEARCH DEVELOPMENTS

Presentations on market research information and new developments in proprietary technology will be presented. Consumer trends and market size information will also be included.

SECTION III

COMMERCIALIZATION: STRATEGIES FOR COMPANIES TO ENTER THE NUTRACEUTICAL MARKET

This section will be divided into two parts:

  1. Presentations on how specific companies are commercializing dietary supplements, medical foods and foods. A special presentation will be made regarding botanical nutraceuticals.
  2. A panel that will discuss (given the nature of the health-medical claim boundaries) ways in which nutraceutical companies can research, develop and commercialize nutraceutical products.

CONFERENCE PARTICIPANTS

Thomas D. AartsExecutive Editor, Nutrition Business Journal

Daniel Best President, Best Vantage, Inc.

Nancy M. Childs, Ph.D.Professor of Food Marketing, St. Joseph's University

Stephen L. DeFelice, M.DChairman, The Foundation for Innovation in Medicine (FIM)

Grant W. Denison, Jr.Chairman and CEO, BioMarin Pharmaceutical, Inc.

Robert G. DonovanConsultant (former Chairman of NDMA (Nonprescription Drug Manufacturers Association))

Victor L. Fulgoni, III, Ph.D.Vice President Worldwide Nutrition Science

W.K. KelloggInstitute for Food and Nutrition Research

Loren D. IsraelsenPresident, LDI Group

Paul A. Lachance, Ph.D.Executive Director, The Nutraceuticals Institute -and- Professor of Nutrition & Food Science, Rutgers University

Louis Lasagna, M.D.Dean, Sackler School of Graduate Biomedical Sciences, Tufts University

Charles H. Manley, Ph.D. Vice President, Science & Technology, Takasago International Corporation

Antonio C. Martinez, 11, Esq.Attorney at Law, Government & Regulatory Affairs Counsel

Stephen H. McNamara, Esq.Hyman, Phelps & McNamara, P.C. (former Associate Chief Counsel for Food, Food & Drug Administration)

W. Patrick Noonan, Esq.Consultant for Regulatory Affairs, Pharmanex, Inc. --and- Law Offices, W. Patrick Noonan, A Professional Corporation

Gerard Pilley, Ph.D.President Directeur General, Grand Public S.A., Paris, France

Charles J. Raubicheck, Esq.Partner, Sidley & Austin (former Associate Chief Counsel for Enforcement, Food & Drug Administration)

John P. Troup, Ph.D.Vice President, Scientific Affairs, General Nutrition Corporation (GNC)

Rhonda WitwerBusiness Development Manager, Monsanto